Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program-Reference-Cited by-同舟云学术

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program

Published:2024-01 Issue: Volume:187 Page:107444
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Passiglia Francesco,Lucia Reale Maria,Lo Russo Giuseppe,Pasello Giulia,Minuti Gabriele,Bulotta Alessandra,Galetta Domenico,Pelizzari Giacomo,Sini Claudio,Bria Emilio,Roca Elisa,Pilotto Sara,Genova Carlo,Metro Giulio,Citarella Fabrizio,Chiari Rita,Cortinovis Diego,Delmonte Angelo,Russo Alessandro,Tiseo Marcello,Cerea Giulio,Carta Annamaria,Scotti Vieri,Vavalà Tiziana,Brambilla Marta,Buffoni Lucio,Buosi Roberta,Catania Chiara,Gori Stefania,Grisanti Salvatore,Agustoni Francesco,Garbo Edoardo^ORCID,Malapelle Umberto,Novello Silvia^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC;Otano;Nat Rev Clin Oncol.,2023

2. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer;Judd;Mol Cancer Ther.,2021

3. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations;Tan;J Clin Oncol.,2022

4. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors;Lee;NPJ Precis Oncol.,2022

5. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC;Negrao;Cancer Discov.,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Response to the Letter to the Editor: Comment on “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib”;Journal of Thoracic Oncology;2024-09

2. Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study;Lung Cancer;2024-08

3. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal;Lung Cancer;2024-05